GT Biopharma Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.86 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $6.20Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $11.2M Enterprise Value $2.3M Shares Outstanding 1.8M diluted Next Earnings Date13 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary GT Biopharma is a clinical-stage immuno-oncology company developing novel therapeutics based on its proprietary natural killer (NK) cell engager TriKE platform. While the company has successfully advanced three candidates into the clinic—with GTB-3650 in an ongoing Phase 1 trial for CD33-expressing hematologic malignancies and GTB-5550 recently dosing its first patient in a Phase 1 solid tumor basket trial—it faces severe financial constraints. With only $9 million in cash as of March 31, 2026, the company's runway only extends through Q4 2026, raising substantial doubt about its ability to continue as a going concern. Additionally, the company must regain compliance with Nasdaq's $1.00 minimum bid price requirement by November 16, 2026. Given the high-risk nature of early-stage oncology development and immediate dilution/delisting risks, a Hold recommendation is warranted until further financing is secured and initial clinical data from the 2H 2026 updates are released. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$3.00 Mean target$3.00 High · most bullish analyst$3.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $0.0220% The company fails to secure additional financing before its cash runway expires in Q4 2026, or is unable to regain compliance with Nasdaq's minimum bid price, leading to delisting to the OTC markets. Alternatively, clinical trials are placed on hold due to unacceptable toxicities (e.g., severe cytokine release syndrome), or show lack of therapeutic efficacy. Base CaseCentral scenario $0.7455% The company successfully completes dose escalation cohorts for GTB-3650 and GTB-5550, demonstrating early safety and biological activity (NK cell activation) in 2H 2026. To address its going concern risk and Nasdaq compliance, the company executes a reverse stock split (approved at the August 2026 shareholder meeting) and raises additional capital through equity or preferred stock issuances, extending its runway into late 2027. Bull CaseUpside scenario $11.0025% The company's pipeline shows highly promising clinical results, leading to a surge in the stock price driven by potential partnership deals or acquisition interest from larger pharmaceutical companies. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |